626   Bone Mineral Density (BMD) in HIV-1-Infected Patients.

E. Negredo*¹, S. Gel¹, E. R. Arisa¹, J. Rosales², R. Paredes¹, L. Del Rio², M. Balagué¹, S. Johnston¹, G. Sirera¹, C. Tural¹, A. Bonjoch¹, A. Jou¹, L. Cruz¹, and B. Clotet¹.
¹Lluita contra la SIDA Fndn., Hosp. Germans Trias i Pujol, Badalona and²CETIR Ctr. Med., Barcelona, Spain.

Background:Our objective was to study the BMD in HIV-1-infected patients (pts), comparing multiple experienced-treated pts with naïve pts.

Methods:A cross-sectional comparative trial was designed to study the BMD of 97 pts. Group A: 49 pre-treated pts and Group B: 24 naïve pts + 24 pts treated <6 months. L2—4 lumbar spine (LS) and neck (NF) and total femur (TF) t, z and DMO scores were analyzed by DEXA scans. Definitions: Normal >-1, osteopenia -1 to -2.5, osteoporosis <-2.5.

Results:Both groups are well-balanced regarding age, gender and body mass index (BMI). No other risk factors for osteoporosis were present in these pts. Group A showed lower mean values in all studied parameters, achieving significant differences in the NF and TF studies (table). Osteopenia or osteoporosis was present in 42 pts in Group A (83.6%) and in 28 in Group B (58.3%). Surprisingly, up to 33% of the 24 naïve pts. presented osteopenia, although none of them presented osteoporosis. No changes were detected when we repeated the analysis excluding women or pts with BMI <20 or >28.

Conclusions:Antiretroviral-experienced pts showed a more accelerated bone mineral loss than naïve-pts, with a higher incidence of osteopenia and osteoporosis. However, naïve pts also presented lower BMD than expected. PIs might play an important role in the pathogenesis of the osteoporosis in these pts, although, other factors could be implicated (duration of HIV infection, nutritional or ovarian-deficient status, etc.). General measures or calcium, vitamin D or other supplements should be considered in HIV-1-infected pts. who received long-term ARV therapy, mainly PI-containing regimens, to prevent bone mineral loss.